These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 28654545)

  • 1. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
    Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
    Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
    Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
    Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
    Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
    Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium.
    DiNorcia J; Florman SS; Haydel B; Tabrizian P; Ruiz RM; Klintmalm GB; Senguttuvan S; Lee DD; Taner CB; Verna EC; Halazun KJ; Hoteit M; Levine MH; Chapman WC; Vachharajani N; Aucejo F; Nguyen MH; Melcher ML; Tevar AD; Humar A; Mobley C; Ghobrial M; Nydam TL; Amundsen B; Markmann JF; Berumen J; Hemming AW; Langnas AN; Carney CA; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
    Ann Surg; 2020 Apr; 271(4):616-624. PubMed ID: 30870180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies.
    El-Gazzaz G; Sourianarayanane A; Menon KV; Sanabria J; Hashimoto K; Quintini C; Kelly D; Eghtesad B; Miller C; Fung J; Aucejo F
    Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):34-41. PubMed ID: 23392796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
    Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K
    Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
    Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
    Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5.
    Macdonald B; Sewell JL; Harper AM; Roberts JP; Yao FY
    Clin Transplant; 2015 Jun; 29(6):506-12. PubMed ID: 25777321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation.
    Lai Q; Vitale A; Iesari S; Finkenstedt A; Mennini G; Onali S; Hoppe-Lotichius M; Manzia TM; Nicolini D; Avolio AW; Mrzljak A; Kocman B; Agnes S; Vivarelli M; Tisone G; Otto G; Tsochatzis E; Rossi M; Viveiros A; Ciccarelli O; Cillo U; Lerut J;
    Liver Transpl; 2019 Jul; 25(7):1023-1033. PubMed ID: 31087772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
    Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN
    Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma.
    Xing M; Sakaria S; Dhanasekaran R; Parekh S; Spivey J; Knechtle SJ; Zhang D; Kim HS
    Cardiovasc Intervent Radiol; 2017 Mar; 40(3):410-420. PubMed ID: 27900445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation.
    Kim PT; Onaca N; Chinnakotla S; Davis GL; Jennings LW; McKenna GJ; Ruiz RM; Levy MF; Goldstein R; Klintmalm GB
    Clin Transplant; 2013; 27(2):311-8. PubMed ID: 23351129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation.
    Zhang W; Kim R; Quintini C; Hashimoto K; Fujiki M; Diago T; Eghtesad B; Miller C; Fung J; Tan A; Menon KV; Aucejo F
    Liver Transpl; 2015 Jan; 21(1):101-11. PubMed ID: 25283528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
    Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
    Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions.
    Chapman WC; Garcia-Aroz S; Vachharajani N; Fowler K; Saad N; Lin Y; Wellen J; Tan B; Khan AS; Doyle MB
    J Am Coll Surg; 2017 Apr; 224(4):610-621. PubMed ID: 28069527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
    Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story.
    Halazun KJ; Najjar M; Abdelmessih RM; Samstein B; Griesemer AD; Guarrera JV; Kato T; Verna EC; Emond JC; Brown RS
    Ann Surg; 2017 Mar; 265(3):557-564. PubMed ID: 27611615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.